Harmony Biosciences Holdings, Inc. (HRMY) research

Harmony Biosciences Holdings, Inc.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$41.53
As of

Harmony Biosciences Holdings, Inc. (HRMY): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.

As of . Source: SEC EDGAR filings for HRMY. Method and limitations.

SHARE THIS CARD

Share the HRMY intelligence card

A branded snapshot of HRMY: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion HRMY intelligence card preview
Post to X
LIVE TERMINAL

See HRMY live in the terminal

Track HRMY's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live HRMY terminal, free

Active signals for HRMY

FREE, NO ACCOUNT

Every signal on HRMY, as it fires

You are seeing 5 of 14 signals recorded on HRMY since 2026-05-30.

The five above all landed on 2026-09-06. The other 9 were recorded on 3 other days. 10 of the 14 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in HRMY (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 413197104 · 2026Q2$43.5M0.06%,
TWO SIGMA INVESTMENTS, LPCUSIP 413197104 · 2026Q2$34.9M0.03%,
MILLENNIUM MANAGEMENT LLCCUSIP 413197104 · 2026Q2$11.6M0.00%,
CITADEL ADVISORS LLCCUSIP 413197104 · 2026Q2$9.3M0.00%,
Bridgewater Associates, LPCUSIP 413197104 · 2026Q2$9.1M0.04%,
D. E. Shaw & Co., Inc.CUSIP 413197104 · 2026Q2$1.9M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, HRMY

HRMY against its peers

HRMY's operating margin of 24.0% ranks in the 92nd percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricHRMYPeer medianPercentilen
Revenue FY868M USD451M USD7521
Gross margin77.2%51.4%936
Operating margin24.0%2.6%9319
Net margin18.3%-2.6%9320
Return on equity18.2%-19.3%8021
P / E15.3x14.2x559

Peers (25): GPCR, SUPN, NKTR, OCUL, BHC, TRVI, NUVB, ANIP, OGN, AMLX, TARS, XERS, OMER, INVA, PAHC, ANRO, ALMS, AMPH, LQDA, AMRX, PCRX, ESPR, ACRS, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (HRMY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more HRMY signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to HRMYand get the insider, 13F, options, and confluence read in one view.

Open the live HRMY terminal, free